Fasting insulin — the upstream marker that moves years before your glucose does

Paired condition: Prediabetes lab results

Quick answer

Fasting insulin measures how hard your pancreas is working to keep glucose normal. It's the single most under-ordered metabolic marker: insulin resistance drives insulin *up* for years while fasting glucose and HbA1c still read "normal." A normal glucose with a high-normal insulin is the classic early-dysfunction pattern — the number that's still reassuring while trouble builds underneath.

Reference ranges and interpretation

Value / populationClassificationWhat it means
2 – 5 µIU/mLOptimalEfficient glucose handling; low insulin resistance.
5 – 10 µIU/mLNormal but worth watchingUpper end often accompanies early insulin resistance.
10 – 15 µIU/mLElevatedInsulin resistance likely underway even if glucose is normal.
> 15 µIU/mLHighMarked insulin resistance; strong metabolic-risk signal.

Assays and units vary (µIU/mL ≈ mIU/L). Most labs flag only values well above these; "in range" is not the same as "optimal." Interpret alongside fasting glucose to calculate HOMA-IR.

Why insulin moves first

Type 2 diabetes develops along a predictable arc. As tissues become resistant to insulin, the pancreas compensates by secreting more insulin — so fasting insulin climbs while fasting glucose stays normal. Only when the pancreas can no longer keep up does glucose (and later HbA1c) begin to rise. The Whitehall II cohort mapped this directly: insulin sensitivity fell and compensatory secretion rose for years before diagnosis. That means fasting glucose and HbA1c are lagging indicators; fasting insulin is one of the earliest routinely-measurable signals.

HOMA-IR: turning two numbers into one

Fasting insulin becomes far more useful paired with fasting glucose via the HOMA-IR index (Homeostasis Model Assessment of Insulin Resistance):
HOMA-IR = (fasting glucose mg/dL × fasting insulin µIU/mL) / 405
- < 1.5 — generally insulin-sensitive
- 1.5 – 2.5 — early/borderline insulin resistance
- > 2.5 — insulin resistance likely
HOMA-IR was validated against the gold-standard euglycemic clamp and correlates well at a population level. It's an estimate, not a diagnosis — but it converts a "normal" glucose and a high-normal insulin into a number that makes the underlying pattern visible.

What to look at alongside fasting insulin

Insulin resistance rarely travels alone. The markers that move with it:
- Fasting glucose — needed for HOMA-IR
- HbA1c — the 3-month glucose average (lags insulin)
- Triglycerides + HDL — triglycerides rise and HDL falls with insulin resistance
- Triglyceride / HDL ratio — a widely used surrogate; < 2.0 is favorable
- ALT — fatty liver frequently accompanies insulin resistance
- Uric acid — often elevated in the same metabolic pattern
- Waist circumference / blood pressure — the non-lab pieces of metabolic syndrome

Phi Longevity reads every marker on every lab you upload — together, against your history, against optimal ranges, and across time. The integrated picture tells you what a single number can't.

Start with my labs →

Frequently asked questions

Why didn't my doctor order fasting insulin?

Fasting insulin isn't part of a standard metabolic panel and isn't required to diagnose diabetes, so it's often skipped. It's most valuable proactively — to catch insulin resistance while it's still reversible — which is exactly the window standard screening tends to miss.

Do I need to fast for this test?

Yes — a true fasting insulin requires 8–12 hours without food, ideally drawn at the same time as fasting glucose so the two can be combined into HOMA-IR. Any recent food will raise insulin and invalidate the interpretation.

Can fasting insulin be too low?

A low fasting insulin with normal glucose usually reflects good insulin sensitivity. Very low insulin with high glucose is a different picture (reduced insulin production) and should be evaluated by a clinician.

How fast can fasting insulin improve?

Faster than HbA1c. Because it reflects current metabolic demand rather than a 3-month average, fasting insulin and HOMA-IR can shift meaningfully within weeks of changes in diet, activity, sleep, and weight — which makes them useful short-term feedback markers.

References

All citations verified against PubMed / publisher of record (see note below for this page's verification date).

  1. 1.Matthews DR, Hosker JP, Rudenski AS, et al. (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28(7):412-419.Original HOMA-IR model — source for the fasting glucose × insulin / 405 formula.PubMed →DOI →
  2. 2.DeFronzo RA, Tobin JD, Andres R. (1979). Glucose clamp technique: a method for quantifying insulin secretion and resistance. American Journal of Physiology. 237(3):E214-E223.The euglycemic clamp — the reference standard HOMA-IR was validated against.PubMed →DOI →
  3. 3.Tabák AG, Jokela M, Akbaraly TN, et al. (2009). Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. The Lancet. 373(9682):2215-2221.Shows insulin sensitivity/secretion changing years before glucose rises — the basis for treating insulin as an early marker.PubMed →DOI →
  4. 4.American Diabetes Association Professional Practice Committee. (2024). Standards of Care in Diabetes—2024. Diabetes Care. 47(Suppl 1):S1-S321.Diagnostic thresholds for glucose/HbA1c that fasting insulin precedes.DOI →

Reference ranges vary by lab and assay. Optimal ranges reflect a proactive, longevity-oriented reading and are more conservative than standard lab flags. This page is educational and not a substitute for individualized medical advice.

By Steve Pinedo

Co-founder, Phi Longevity

Last updated: 2026-07-20

Steve Pinedo is the Co-founder of Phi Longevity, the AI application that turns a confusing stack of lab reports, wearable data, and clinical notes into a single, integrated picture of your health. He started Phi Longevity to make proactive health and wellness far easier to achieve. He realized how difficult it was for clients to manage their own care, records and coordination so he assembled a comprehensive M.D. led clinical team behind the platform, packaging the proactive-care experience that delivered measurable outcomes (lower triglycerides, reduced body fat, improved LDL, balanced hormones, relief from long-running autoimmune conditions) for any patient with a complicated lab to use now with an application. More about Phi Longevity →

Related